A new compound is drawing serious attention in the amylin research space, and the data behind it is worth understanding if you follow peptide and metabolic research closely. Eloralintide is a selective amylin receptor agonist, and both its standalone results and its early combination results with tirzepatide have made it one of the most discussed compounds in obesity research right now.
Here is a breakdown of what eloralintide is, how the amylin pathway works, and what the published and early stage data actually shows.
What Eloralintide Is
Eloralintide is an investigational, once weekly selective amylin receptor agonist, previously referred to in research literature as LY3841136. It is being developed by Eli Lilly, the same company behind tirzepatide, but it works through a different biological pathway than the GLP-1 compounds most people in this space are already familiar with.
The distinction matters. Semaglutide and tirzepatide are incretin based therapies that act on GLP-1 (and in tirzepatide’s case, GIP) receptors. Eloralintide instead mimics amylin, a hormone with its own separate signaling pathway. That is part of why the compound has generated so much interest on its own, and why it is being studied in combination with existing GLP-1 therapies.
Eloralintide is also described as a selective amylin receptor agonist, sometimes shortened to SARA. That selectivity for the amylin receptor specifically, rather than related receptors, appears to be central to its results.
How Amylin Works
Amylin is a hormone naturally released alongside insulin by the pancreas after eating. It functions as part of the body’s satiety signaling system.
Three effects are relevant to weight research:
Appetite signaling. Amylin acts on the area postrema, a region of the brainstem that sits outside the blood brain barrier and can directly sense circulating hormones. This produces a sustained feeling of fullness.
Gastric emptying. Amylin slows the rate at which food leaves the stomach, extending the feeling of fullness after a meal.
Glucagon suppression. Amylin helps blunt the post meal glucagon spike, which plays a role in blood sugar regulation.
Some of this overlaps with what GLP-1 compounds do, which is why the two classes are being studied together rather than treated as competitors.
Amylin Compounds Are Not New, But Selectivity Is the Differentiator
Cagrilintide, developed by Novo Nordisk, is the amylin analog most familiar to people in the peptide research space, largely due to its combination with semaglutide in CagriSema.
What sets eloralintide apart in early research is its selectivity for the amylin receptor over the related calcitonin receptor. Compounds that activate both amylin and calcitonin receptors tend to produce more off target activity. Cagrilintide has meaningful calcitonin receptor activity, and there is a growing view in the research community that this activity may partly explain why CagriSema underperformed relative to initial expectations. Eloralintide’s higher selectivity for the amylin receptor specifically is designed to reduce that off target activity while still delivering the metabolic effects of amylin signaling.
Phase 2 Monotherapy Data
The Phase 2 trial results were presented at ObesityWeek 2025 and published in The Lancet.
At 48 weeks, every treatment arm met the primary endpoint, with mean weight reductions ranging from 9.5 percent to 20.1 percent compared to 0.4 percent with placebo. The trial included 263 adults with obesity or overweight and at least one weight related comorbidity, excluding those with type 2 diabetes. Weight loss was dose dependent, with the highest dose arm (9mg) producing the 20.1 percent mean reduction from baseline.
That places eloralintide’s monotherapy results in a similar range to tirzepatide and ahead of semaglutide monotherapy, through a distinct mechanism.
On tolerability, the most commonly reported effects were mild to moderate nausea and fatigue. GI related effects in the lower dose arms were reported at rates similar to placebo, which is notable given how central GI tolerability issues have been to the GLP-1 conversation.
Early Combination Data With Tirzepatide
The monotherapy numbers got attention. The early combination data is what has pushed eloralintide further into the spotlight.
Phase 1b results shared ahead of EASD 2026 looked at eloralintide paired with tirzepatide across several dosing cohorts:
- In a 16 week cohort combining 3mg eloralintide with a lower 5mg dose of tirzepatide, the pairing produced roughly 17 percent weight loss with minimal dropout. For comparison, that is a similar magnitude of weight loss to what 2.4mg semaglutide produces over 72 weeks, reached in less than a quarter of the time.
- In a 32 week cohort using the maximum 15mg tirzepatide dose, adding eloralintide pushed weight loss as high as 29 percent in one arm, approaching numbers previously associated with retatrutide or bariatric surgery, in a notably shorter timeframe.
- In a 24 week head to head cohort, eloralintide monotherapy produced about 14.2 percent weight loss, tirzepatide monotherapy about 16.4 percent, and the combination reached 25.5 percent, suggesting the two mechanisms may be additive rather than redundant.
Important context: these are small, early stage Phase 1b results with limited participants per arm, and some of the highest dose cohorts saw notable dropout. Some of that dropout may be related to the pace of weight loss itself being difficult to sustain. This is proof of concept data, not large scale confirmation, and should be read that way.
The Pace of Weight Loss Is Its Own Consideration
One theme worth understanding on its own: some of the combination data shows weight loss happening quite fast. Losing 25 to 29 percent of body weight within six to eight months is faster than the roughly 80 weeks retatrutide needed to reach comparable numbers in its own trials.
Rapid weight loss carries a general research consideration regardless of compound: the faster the loss, the greater the risk that lean mass is lost alongside fat mass. This is part of why Lilly appears to be studying eloralintide as an add on approach as well, introducing it after weight loss has plateaued on an existing GLP-1 therapy rather than starting both compounds simultaneously. That sequencing may prove to be a more sustainable approach for many people, though it is still being studied.
How Eloralintide Compares to GLP-1 Compounds
The core difference is mechanism. GLP-1 agonists act through incretin pathways, affecting glucose dependent insulin secretion, hypothalamic appetite regulation, and gastric emptying. Amylin agonists like eloralintide act through brainstem satiety centers and their own gastric motility signaling. Both classes reduce appetite and slow gastric emptying, but they reach that outcome through separate biological routes.
This is precisely why the two classes are being studied together. Two independent satiety pathways activated at once appears to produce an additive effect, which is the same principle behind CagriSema, though eloralintide’s receptor selectivity appears to be a meaningful difference in how well that combination performs.
There is also early interest in whether amylin’s distinct mechanism affects body composition differently than GLP-1 alone, specifically the ratio of fat loss to lean mass loss. This is an open research question, not an established finding.
Where Development Stands
Eloralintide remains investigational. It is not FDA approved and is not available outside of clinical trials.
Based on the Phase 2 monotherapy results, the compound has moved into Phase 3 testing as a standalone therapy. Multiple combination studies are ongoing in parallel, including the tirzepatide pairing and an add on protocol for people who have plateaued on existing incretin therapy. A Phase 2 study of eloralintide combined with tirzepatide in people with type 2 diabetes is expected to complete later in 2026.
Phase 3 trials are the large scale studies that typically precede any regulatory submission, so eloralintide has a clear path forward but remains a meaningful distance from any potential approval.
Frequently Asked Questions
What is eloralintide?
An investigational, once weekly selective amylin receptor agonist developed by Eli Lilly, previously known as LY3841136. Phase 2 data showed up to 20.1 percent mean weight loss as a standalone compound, with early combination data with tirzepatide reaching over 25 percent in some cohorts.
How is eloralintide different from semaglutide or tirzepatide?
Semaglutide and tirzepatide work through GLP-1 (and GIP, in tirzepatide’s case) incretin pathways. Eloralintide works through the amylin pathway, a separate satiety mechanism centered on the brainstem and gastric motility. Because the pathways are independent, research suggests they may combine for an additive effect rather than overlapping redundantly.
How much weight loss has eloralintide produced in trials?
As a standalone in Phase 2, 9.5 to 20.1 percent over 48 weeks depending on dose. In early Phase 1b combination studies with tirzepatide, some cohorts reached 25 to 29 percent, though these are small early stage results.
How is eloralintide different from cagrilintide?
Both are amylin agonists, but eloralintide is designed to be more selective for the amylin receptor over the related calcitonin receptor. Cagrilintide has more calcitonin receptor activity, which some researchers believe may have limited CagriSema’s real world performance relative to expectations.
Is eloralintide approved for use?
No. It remains investigational, currently in Phase 3 monotherapy trials with combination studies ongoing.
Can eloralintide be combined with tirzepatide?
That combination is under active study. Early Phase 1b data shows an additive effect on weight loss, though the sample sizes are small and the rapid pace of loss in some cohorts raises open questions about optimal dosing and sequencing.
How often is eloralintide dosed in current trials?
Once weekly, consistent with the leading GLP-1 and dual agonist compounds currently available.
This article is for informational and research purposes only. Eloralintide is an investigational compound and is not approved for human use outside of clinical trials. Nothing in this article constitutes medical advice.